Improving transparency in clinical trial reporting.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40294530.
- Also identified by DOI 10.1371/journal.pmed.1004588 and PMC identifier 12037211.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The power to interpret the results of randomised clinical trial results relies on transparent reporting of the study design, protocol, methods and analyses. Without such clarity, the benefits of the findings, to both healthcare, policy and research, cannot be realized in full. The publication of the updated CONSORT 2025 and SPIRIT 2025 statements for reporting of randomised clinical trials and protocols, respectively, offers the opportunity to reflect on the power that transparent reporting of clinical trial design and data offers to improve the quality of trials and outcomes.
Medical subject headings
- Randomized Controlled Trials as Topic
- Research Design
- Clinical Trials as Topic